Clinical Trial

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-08-07
notable Enrollment increased: 332 -> 388 participants 2026-08-07
notable Trial sites expanded: 31 -> 36 locations 2026-08-07
Trial Details
NCT Number NCT07317934
Lead Sponsor Innostellar Biotherapeutics Co.,Ltd
Conditions Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Enrollment 388 participants
Start Date 2026-01-14
Primary Completion 2028-03 (estimated)
Study Completion 2032-06-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-06